Neurimmune Therapeutics

Neurimmune Therapeutics AG is an emerging biotechnology company dedicated to the identification of novel therapeutics for the treatment of human diseases with a focus on neurodegenerative disorders such as Alzheimer’s disease.

Based on its unique technology platform RTM™ (Reverse Translational Medicine) Neurimmune’s lead programs focus on the development of proprietary human antibodies as therapeutics and are currently in preclinical development. Neurimmune’s approach to antibody drug discovery provides a number of unique advantages that result in a superior risk profile compared to traditional antibody drug discovery approaches substantially increasing the speed to IND and clinical proof of concept.